Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta

Journal of Neuroimmunology

Volumn 280, Issue , 2015, Pages 12-15

  Åivo, Julia ^a   Hänninen, Arno ^b   Ilonen, Jorma ^b   Soilu Hänninen, Merja ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cytokines; Multiple sclerosis; TGF beta; Vitamin D

Indexed keywords

COLECALCIFEROL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; LATENCY ACTIVATED PEPTIDE; PEPTIDE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; VITAMIN; VITAMIN D;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GAMMA INTERFERON BLOOD LEVEL; HUMAN; IMMUNOMODULATION; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 13 BLOOD LEVEL; INTERLEUKIN 17 BLOOD LEVEL; INTERLEUKIN 1BETA BLOOD LEVEL; INTERLEUKIN 2 BLOOD LEVEL; INTERLEUKIN 22 BLOOD LEVEL; INTERLEUKIN 4 BLOOD LEVEL; INTERLEUKIN 5 BLOOD LEVEL; INTERLEUKIN 6 BLOOD LEVEL; INTERLEUKIN 9 BLOOD LEVEL; LATENCY ACTIVATED PEPTIDE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; TRANSFORMING GROWTH FACTOR BETA BLOOD LEVEL; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; CLINICAL TRIAL; FOLLOW UP; MAJOR HISTOCOMPATIBILITY COMPLEX; MIDDLE AGED; TIME; YOUNG ADULT;

ADULT; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; VITAMINS; YOUNG ADULT;

EID: 84924778323     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.01.005     Document Type: Article

References (36)

1. Adams J.S., Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4(2):80.
2. Adorini L., Penna G., Giarratana N., Roncari A., Amuchastegui S., Daniel K.C., Uskokovic M. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J. Steroid Biochem. Mol. Biol. 2004, 89-90(1-5):437-441.
3. Åivo J., Lindström B.M., Soilu-Hänninen M. A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult. Scler. Int. 2012, 802796.
4. Allen A.C., Kelly S., Basdeo S.A., Kinsella K., Mulready K.J., Mills K.H., Tubridy N., Walsh C., Brady J.J., Hutchinson M., Fletcher J.M. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult. Scler. 2012, 18(12):1797-1800.
5. Ascherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol. 2010, 9(6):599-612.
6. Ascherio A., Munger K.L., White R., Köchert K., Simon K.C., Polman C.H., Freedman M.S., Hartung H.P., Miller D.H., Montalbán X., Edan G., Barkhof F., Pleimes D., Radü E.W., Sandbrink R., Kappos L., Pohl C. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014, 71(3):306-314.
7. Burton J.M., Kimball S., Vieth R.A. Phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74(23):1852-1859.
8. Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 1998, 160(11):5314-5319.
9. 3: a transcriptional modulator of the IFN-γ gene. Eur. J. Immunol. 1998, 28(10):3017-3030.
10. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
11. D'Ambrosio D., Cippitelli M., Cocciolo M.G., Mazzeo D., Di Lucia P., Lang R., Sinigaglia F., Panina-Bordignon P. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. Clin Invest. 1998, 101(1):252-262.
12. DiDonato J.A., Mercurio F., Karin M. NF-κB and the link between inflammation and cancer. Immunol. Rev. 2012, 246(1):379-400.
13. Golan D., Haltal B., Glass-Marmor L., Staun-Ram E., Rozenber O., Lavi I., Dishon S., Barak M., Ish-Shalom S., Miller A. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomised controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol. 2013, 13:60.
14. Hermann R., Turpeinen H., Laine A.P., Veijola R., Knip M., Simell O., Sipilä I., Akerblom H.K., Ilonen J. HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 2003, 62:162-169.
15. Hyytiäinen M., Penttinen C., Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit. Rev. Clin. Lab. Sci. 2004, 41(3):233-264.
16. Ikeda U., Wakita D., Ohkuri T., Chamoto K., Kitamura H., Iwakura Y., Nishimura T. Immunol. Lett. 2013, 134(1):7-16.
17. Jorde R., Sneve M., Torjesen P.A., Figenschau Y., Gøransson L.G., Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010, 50:175-180.
18. Joshi S., Pantalena L.C., Liu X.K., Gaffen S.L., Liu H., Rohowsky-Kochan C., Ichiyama K., Yoshimura A., Steinman L., Christakos S., Youssef S. 1,25-Dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol. Cell. Biol. 2011, 31(17):3653-3669.
19. Jurutka P.W., Whitfield G.K., Hsieh J.C., Thompson P.D., Haussler C.A., Haussler M.R. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev. Endocr. Metab. Disord. 2001, 2(2):203-216.
20. Li M.O., Sanjabi S., Flavell R.A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006, 25(3):455-471.
21. Mahon B.D., Gordon S.A., Cruz J., Cosman F., Cantorna M.T. Cytokine profiles in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 2003, 134(1-2):128-132.
22. Martinelli V., Dalla Costa G., Colombo B., Dalla Libera D., Rubinacci A., Filippi M., Furlan R., Comi G. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult. Scler. 2014, 20(2):147-155.
23. Mowry E.M., Waubant E., McCulloch C.E., Okuda D.T., Evangelista A.A., Lincoln R.R., Gourraud P.A., Brenneman D., Owen M.C., Qualley P., Bucci M., Hauser S.L., Pelletier D. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann. Neurol. 2012, 72(2):234-240.
24. Palmer M.T., Lee Y.K., Maynard C.L., et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector T cells. J. Biol. Chem. 2011, 286(2):997-1004.
25. Runia T.F., Hop W.C., de Rijke Y.B., Buljevac D., Hintzen R.Q. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012, 79:261-266.
26. Simpson S., Taylor B., Blizzard L., Ponsonby A.L., Pittas F., Tremlett H., Dwyer T., Gies P., van der Mei I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 2010, 68(2):193-203.
27. Smolders J., Damoiseaux J., Menheere P., Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 2008, 194(1-2):7-17.
28. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 2008, 14(9):1220-1224.
29. Smolders J., Thewissen M., Peelen E., Menheere P., Tervaert J.W., Damoiseaux J., Hupperts R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009, 4(8):e6635.
30. Smolders J., Peelen E., Thewissen M., Cohen Tervaert J.W., Menheere P., Hupperts R., Damoiseaux J. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010, 5(12):e15235.
31. Soilu-Hänninen M., Laaksonen M., Laitinen I., Erälinna J.P., Lilius E.M., Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2008, 79(2):152-157.
32. Soilu-Hänninen M., Aivo J., Lindström B.M., Elovaara I., Sumelahti M.L., Färkkilä M., Tienari P., Atula S., Sarasoja T., Herrala L., Keskinarkaus I., Kruger J., Kallio T., Rocca M.A., Filippi M. A randomized double-blind placebo-controlled trial with vitamin D3 as an add-on treatment to interferon beta for the treatment of MS. J. Neurol. Neurosurg. Psychiatry 2012, 83(5):565-571.
33. Stassen M., Schmitt E., Bopp T. From interleukin-9 to T helper 9 cells. Ann. N. Y. Acad. Sci. 2012, 1247:56-68.
34. 3-mediated effects. J. Immunol. 1998, 160(1):209-218.
35. + T cells. Eur. J. Immunol. 2012, 42(10):2697-2708. (Oct, Epub 2012 Aug 20). 10.1002/eji.201242370.
36. van der Aar A.M., Sibiryak D.S., Bakdash G., van Capel T.M., van der Kleij H.P., Opstelten D.J., Teunissen M.B., Kapsenberg M.L., de Jong E.C. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J. Allergy Clin. Immunol. 2011, 127(6):1532-1540.